Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
June 11, 2021 16:11 ET
|
Sorrento Therapeutics, Inc.
Large Phase 2 efficacy trial cleared to start in the United Kingdom in newly diagnosed SARS-CoV-2 infected patients.COVI-DROPS is administered by intranasal drops and the antibody is active against...
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
March 02, 2021 16:02 ET
|
Sorrento Therapeutics, Inc.
FDA granted IND clearance today for the commencement of a Phase 1 safety and pharmacokinetic study for STI-2099 (COVIDROPS™) in healthy volunteers and outpatients with mild COVID-19 disease with or...
Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein
January 19, 2021 17:06 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation...
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients
December 09, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
FDA has granted clearance for the commencement of Phase 1 clinical trials of STI-2020 (COVI-AMGTM) in healthy volunteers and COVID-19 patients with mild symptoms.STI-2020, a monoclonal antibody, has...
DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies
November 27, 2020 08:00 ET
|
Sorrento Therapeutics, Inc.
Initial funding of up to $34 million for the project “Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus” (HR0011-21-9-0015) to support the development of...
Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2
November 11, 2020 09:00 ET
|
Sorrento Therapeutics, Inc.
IND filing today for STI-2099 (COVI-DROPS™) for a phase 1 safety and pharmacokinetic study in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous...
Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID-19
October 07, 2020 15:10 ET
|
Sorrento Therapeutics, Inc.
In preclinical studies, Salicyn-30, a small molecule, demonstrated potent in-vitro viral load reduction of 3-4 log in SARS-CoV-2 infection model in normal healthy VERO E6 cells.Salicyn-30 displays a...
Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2
September 28, 2020 23:59 ET
|
Sorrento Therapeutics, Inc.
In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.Both STI-1499 and...